UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~February 23~~March 19, 2026

INHIBRX BIOSCIENCES, INC.

(Exact name of registrant as specified in its charter)

Delaware

001-42031

99-0613523

(State or other jurisdiction
of incorporation)

(Commission
File Number)

(IRS Employer
Identification No.)

11025 N. Torrey Pines Road, Suite 140

La Jolla, CA 92037

(Address of Principal Executive Offices and Zip Code)

Registrant’s telephone number, including area code: (858) 795-4220

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.0001 per share	INBX	The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

Item 7 2.0102 Results ~~Regulation~~of FDOperations ~~Disclosure.~~and Financial Condition

On ~~February 23~~March 19, 2026, Inhibrx Biosciences, Inc. (the “Company”) ~~posted~~issued ana ~~updated~~press ~~copy~~release ofannouncing its ~~corporate~~financial ~~presentation~~results tofor the ~~“Investors”~~year ~~tab~~ended ofDecember ~~its~~31, ~~website at www~~2025.~~inhibrx.com.~~ ~~The~~A ~~presentation~~copy isof ~~attached~~the topress ~~this~~release ~~Current~~is ~~Report~~furnished ~~on Form 8-K~~ as Exhibit 99.1. ~~The Company from time~~ to ~~time~~this ~~presents and/or distributes the presentation to the investment community during conferences and meetings to provide updates and summaries of its business~~report. ~~The Company undertakes no obligation to update, supplement, or amend the materials attached hereto as Exhibit 99.1.~~

The information in Item 72.0102 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any ~~other~~ filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.						Description
99.1						~~Corporate~~Press ~~Presentation~~Release issued by Inhibrx Biosciences, Inc. on March 19, 2026
104						Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: February 23, 2026
Date: March 19, 2026
	INHIBRX BIOSCIENCES, INC.
	By:	/s/ Kelly Deck
	Name:	Kelly Deck
	Title:	Chief Financial Officer

Filing Compare · Inhibrx Biosciences, Inc.